Paris, France – 2 Sept 2019: Early intensive vasodilation does not improve 180-day all-cause mortality and rehospitalisation in patients hospitalised for acute heart failure, according to late breaking results of the GALACTIC trial presented in a Hot Line Session today at ESC Congress 2019 together with the World Congress of Cardiology. (1)
Acute heart failure is the most common diagnosis in the emergency department leading to hospitalisation. In contrast to the enormous improvements achieved in the management of patients with chronic heart failure, morbidity and mortality remain unacceptably high in patients with acute heart failure. Around half of patients die or are back in hospital within six months.
Two pilot studies showed that early initiation of high-dose intravenous nitrates targeted to arterial blood pressure improved outcome in acute pulmonary oedema, a dramatic phenotype occurring in about 5% of acute heart failure patients. It is unknown whether this aggressive vasodilation would provide comparable benefits in the vast majority of acute heart failure patients, who are haemodynamically stable and do not require ventilator support after initial treatment in the emergency department. In these patients, fixed-dose infusions of novel vasodilators over a short period (24 to 48 hours) have not improved outcomes.
The GALACTIC trial tested the hypothesis that early goal-directed therapy with maximal and persistent vasodilation would lead to better clinical outcomes than standard care.
A total of 781 patients presenting with acute heart failure at the emergency department were randomly allocated to early goal-directed therapy or standard care according to ESC guidelines (2) until hospital discharge.
Early goal-directed therapy combined high and personalised doses of universally available and inexpensive vasodilators including sublingual and transdermal nitrates, oral hydralazine for 48 hours to avoid tolerance to nitrates, and rapid uptitration of ACE inhibitors or angiotensin II receptor blockers. The ACE inhibitor dose targeted at discharge was higher than the standard dose; it was therefore hypothesised that patients in the intervention group would continue to receive higher doses during most of the six-month follow-up.
All other therapies including loop diuretic dose and duration, beta-blockers, aldosterone antagonists, and cardiac devices were administered according to ESC guidelines and at the discretion of the treating physician.
The primary endpoint was a composite of all-cause mortality or rehospitalisation for acute heart failure at 180 days. Secondary endpoints included quantitative assessment of dyspnoea on days two and six.
Patients were randomised at a median of five hours after presentation. Dyspnoea improved in both groups without significant between-group differences. Clinical follow-up at 180 days was completed in 779 patients (99.7%). All-cause death or adjudicated acute heart failure rehospitalisation through day 180 occurred in 117 and 111 patients in the early intensive vasodilation and standard care groups, respectively (30.6% versus 27.8%; adjusted hazard ratio 1.07; 95% confidence interval 0.83–1.39; p=0.589).
Predefined subgroup analyses showed consistent results according to age and left ventricular ejection fraction. However, there was a statistically significant interaction (interaction p value 0.027) of the treatment effect with sex, suggesting that early goal-directed therapy might possibly even harm women.
Principal investigator Professor Christian Mueller of University Hospital Basel, Switzerland said: “This study extends and corroborates neutral findings from previous work on the treatment of acute heart failure patients, particularly three large phase III trials of novel vasodilators (neseritide, ularitide, and serelaxin) and a moderate-size investigator-initiated direct comparison of diuretic strategies.”
He concluded: “Overall, these trials suggest that short-term interventions may not influence long-term outcomes in the heterogeneous acute heart failure population, even using individualised and aggressive dosing strategies as applied in this trial. From a broader perspective, these trials also suggest that while pulmonary congestion is the hallmark of acute heart failure, it may not be the ideal target for novel therapies.”
ENDS
Our mission: To reduce the burden of cardiovascular disease.